MLTX - CIK 0001821586
The table below shows MoonLake Immunotherapeutics's income statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| R&D | $202.86M | $112.77M | $31.80M | $42.05M | - |
| SG&A | $41.97M | $30.32M | $22.32M | $23.01M | $4.57M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Operating income |
| -$244.83M |
| -$143.09M |
| -$54.12M |
| -$65.06M |
| -$4.57M |
| Income tax | $611.00K | $282.00K | $94.00K | $36.37K | - |
| Net income | -$227.32M | -$118.94M | -$36.01M | -$49.97M | -$4.54M |
| EPS (diluted) | -$3.53 | -$1.89 | -$0.73 | -$1.70 | - |